A Phase 2 interventional study of LUM-201 and rhGH Norditropin® pen (34 µg/kg) in Growth Hormone Deficiency, sponsored by Lumos Pharma. Completed at 43 sites in 6 countries. Open to participants aged 3 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-06-17.
Sponsored by Lumos Pharma · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies in Dwarfism, Pituitary with a site in United States — 11 open to participants now, 12 under way, 3 of them phase 3. Dwarfism, Pituitary · United States.
Among the 89 studies in Dwarfism, Pituitary with a site in United States, this one is the 17th largest by enrollment of the 66 interventional ones that give a count, is one of 2 that started in 2020, is one of 15 in phase 2, and was the 75th registered.
252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.
Browse Dwarfism, Pituitary studies →11 of the 89 studies in Dwarfism, Pituitary with a site in United States are open now. Recruiting first, the newest first:
Lumos Pharma · Sites in United States, Argentina, Australia and 5 more countries
Ages 3–11
VA Office of Research and Development · Sites in United States
Ages 21–55
Baylor College of Medicine · Sites in United States
Ages 18–64
Columbia University · Sites in United States
Ages 18–45 · Healthy volunteers
Ascendis Pharma Endocrinology Division A/S · Sites in United States
Ages 1–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.
This study: 3 Years to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 19 · Phase 3 24 · Phase 4 10
First in 1993; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 104 is above the median of 60 across 169 interventional studies indexed under Dwarfism, Pituitary.
Median enrollment 49 across the 66 interventional studies, 27 across the 21 observational. Of the 74 that completed or were terminated, 33 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 89 have an industry lead sponsor. The 10 most frequent:
This study is registered under Lumos Pharma, one of the names counted as Lumos Pharma, Inc.. Under that name alone:
Lumos Pharma is the lead sponsor of 8 studies on the registry; 5 are open to participants now.
Lumos Pharma, Inc. has 6 studies filed under Dwarfism, Pituitary — fewer than ten, so there is no comparison to draw.
2 of the studies in Dwarfism, Pituitary with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04867317Phase 3VA Office of Research and DevelopmentGrowth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD) | 2027-02-28 |
| NCT05355272Baylor College of MedicineGrowth Hormone Replacement in Veterans With GWI and AGHD (GWIT) | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 89 studies in Dwarfism, Pituitary with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multi-national trial. The goals of the trial are to study LUM-201 as a possible treatment for Pediatric Growth Hormone Deficiency (PGHD) and investigate a predictive enrichment marker (PEM) strategy to select subjects likely to respond to therapy with LUM-201.
This trial will have one screening visit with tests to assess if subjects are eligible to start study therapy. Once subjects have completed screening, and if they are determined to be eligible, they will be randomized to receive one of three oral daily doses of LUM-201 or daily injections of recombinant human growth hormone (rhGH). All subjects will have an equal chance of being placed in any of the four groups.
The trial consists of up to 24 months of treatment. After screening, subjects will return to the clinic for 6 (subjects placed in rhGH group) or 10 visits (subjects placed in LUM-201 group). During several of these clinic visits, subjects will have a physical exam, blood, and urine collections. There will also be 3 phone calls with study staff that will take place between the clinic visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: LUM-201
Drug: LUM-201
Drug: LUM-201
Drug: rhGH Norditropin® pen (34 µg/kg)
Administered orally once daily
Administered subcutaneously (s.c., under the skin) once daily.
Percentage of Participants With a Positive Growth Response From Day 1 to Month 6 (AHV >= 6.85 cm/yr)
Annualized height velocity (AHV); Height is measured in triplicate, by a calibrated stadiometer and taking the mean value AVH equation is (h2-h1/t2-t1)\*365.25; h1 = height measured at day 1 h2 = height measured at month 6 t1 = day 1 t2 = month 6
Time frame: Day 1 to Month 6
AHV After 6 Months on LUM-201 Compared to rhGH
Annualized height velocity to be measured.
Time frame: Day 1 to Month 6
Percentage of Participants With a Positive Result on Both PEM Tests (at Screening and on Day 1)
PEM Test Reproducibility Safety Population
Time frame: Screening to Day 1
Change in Height Standard Deviation Score (SDS)
Full Analysis Set Population month 6
Time frame: Day 1 to Month 6
Change in Height Standard Deviation Score (SDS)
Full Analysis Set Population month 12
Time frame: Day 1 to Month 12
Change in Weight From Baseline
Change in Weight from baseline
Time frame: Day 1 to Month 6
Change in Weight From Baseline
Change in Weight from baseline
Time frame: Day 1 to Month 12
Change in Weight SDS
Change in Weight-SDS (Standard Deviation Score)
Time frame: Day 1 to Month 6
Change in Weight SDS
Change in Weight-SDS (Standard Deviation Score)
Time frame: Day 1 to Month 12
Change in Body Mass Index (BMI)
Change in BMI from baseline
Time frame: Day 1 to Month 6
Change in BMI
Change in BMI (Body Mass Index) from baseline
Time frame: Day 1 to Month 12
Change in BMI SDS
Change in BMI SDS
Time frame: Day 1 to Month 6
Change in BMI SDS
Change in BMI SDS This is not a Z-Score analysis. Standard deviation score of 0 is the population mean for the age/sex. Normal range is typically -2 to +2 SDS. A positive score is an improvement and a negative score a decrease.
Time frame: Day 1 to Month 12
Bone Age
Change in bone age, measured by X-ray of left hand and wrist using Greulich \& Pyle atlas
Time frame: Day 1 to Month 6
Bone Age
Change in bone age, measured by X-ray of left hand and wrist using Greulich \& Pyle atlas
Time frame: Day 1 to Month 18
Pharmacokinetics of LUM-201
Serum concentrations at 30 minutes (Cmax/Steady State)
Time frame: Day 1 to Month 6
Growth Hormone (GH) Concentration on Maintenance Treatment
Serum GH concentration
Time frame: Month 6
Growth Hormone (GH) Concentration on Maintenance Treatment
Serum GH concentration
Time frame: Month 12
Insulin-like Growth Factor 1 SDS
Serum concentrations of insulin-like growth factor 1 This is not a Z-Score analysis. Standard deviation score of 0 is the population mean for the age/sex. Normal range is typically -2 to +2 SDS. A positive score is an improvement and a negative score a decrease.
Time frame: Month 6
Insulin-like Growth Factor 1 SDS
Serum concentrations of insulin-like growth factor 1 This is not a Z-Score analysis. Standard deviation score of 0 is the population mean for the age/sex. Normal range is typically -2 to +2 SDS. A positive score is an improvement and a negative score a decrease.
Time frame: Month 12
| Milestone | Predictive Enrichment Marker (PEM) Dose LUM-201 (0.8 mg/kg/Day) | LUM-201 (0.8 mg/kg/Day) | LUM-201 (1.6 mg/kg/Day) | LUM-201 (3.2 mg/kg/Day) | rhGH (34 µg/kg/Day) |
|---|---|---|---|---|---|
| Started | 104 | 0 | 0 | 0 | 0 |
| Completed | 82 | 0 | 0 | 0 | 0 |
| Not completed | 22 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 22 | 0 | 0 | 0 | 0 |
| Milestone | Predictive Enrichment Marker (PEM) Dose LUM-201 (0.8 mg/kg/Day) | LUM-201 (0.8 mg/kg/Day) | LUM-201 (1.6 mg/kg/Day) | LUM-201 (3.2 mg/kg/Day) | rhGH (34 µg/kg/Day) |
|---|---|---|---|---|---|
| Started | 0 | 18 | 22 | 22 | 20 |
| Completed | 0 | 5 | 6 | 8 | 18 |
| Not completed | 0 | 13 | 16 | 14 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 | 2 | 0 | 2 |
| Withdrew: Failed annualized height velocity criteria, or transitioned to extension study early. | 0 | 12 | 13 | 14 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 0 |
Annualized height velocity (AHV); Height is measured in triplicate, by a calibrated stadiometer and taking the mean value AVH equation is (h2-h1/t2-t1)\*365.25; h1 = height measured at day 1 h2 = height measured at month 6 t1 = day 1 t2 = month 6
| percentage of participants | LUM-201 (0.8 mg/kg/Day) | LUM-201 (1.6 mg/kg/Day) | LUM-201 (3.2 mg/kg/Day) | Recombinant Human Growth Hormone (rhGH) (34 µg/kg/Day) |
|---|---|---|---|---|
| Percentage of Participants With a Positive Growth Response From Day 1 to Month 6 (AHV >= 6.85 cm/yr) | 44.4 | 72.7 | 72.7 | 100 |
Annualized height velocity to be measured.
| centimeters per year | LUM-201 (0.8 mg/kg/Day) | LUM-201 (1.6 mg/kg/Day) | LUM-201 (3.2 mg/kg/Day) | rhGH (34 µg/kg/Day) |
|---|---|---|---|---|
| AHV After 6 Months on LUM-201 Compared to rhGH | 6.7575 ± 1.30141 | 8.2135 ± 1.88092 | 7.7342 ± 1.79706 | 10.5739 ± 2.04380 |
PEM Test Reproducibility Safety Population
| percentage of participants | Subjects With Positive Agreement on PEM Tests |
|---|---|
| Percentage of Participants With a Positive Result on Both PEM Tests (at Screening and on Day 1) | 100 (95.4 to 100) |
Full Analysis Set Population month 6
| Standard Deviation Score | LUM-201 (0.8 mg/kg/Day) | LUM-201 (1.6 mg/kg/Day) | LUM-201 (3.2 mg/kg/Day) | rhGH (34 µg/kg/Day) |
|---|---|---|---|---|
| Change in Height Standard Deviation Score (SDS) | 0.108 ± 0.1230 | 0.238 ± 0.1767 | 0.215 ± 0.1716 | 0.444 ± 0.1810 |
Full Analysis Set Population month 12
| Standard Deviation Score | LUM-201 (0.8 mg/kg/Day) | LUM-201 (1.6 mg/kg/Day) | LUM-201 (3.2 mg/kg/Day) | rhGH (34 µg/kg/Day) |
|---|---|---|---|---|
| Change in Height Standard Deviation Score (SDS) | 0.207 ± 0.2359 | 0.370 ± 0.2786 | 0.369 ± 0.2514 | 0.732 ± 0.2424 |
Change in Weight from baseline
| kg | LUM-201 (0.8 mg/kg/Day) | LUM-201 (1.6 mg/kg/Day) | LUM-201 (3.2 mg/kg/Day) | rhGH (34 µg/kg/Day) |
|---|---|---|---|---|
| Change in Weight From Baseline | 2.392 ± 1.3859 | 2.680 ± 1.2710 | 2.530 ± 0.7133 | 1.737 ± 0.6940 |
Change in Weight from baseline
| kg | LUM-201 (0.8 mg/kg/Day) | LUM-201 (1.6 mg/kg/Day) | LUM-201 (3.2 mg/kg/Day) | rhGH (34 µg/kg/Day) |
|---|---|---|---|---|
| Change in Weight From Baseline | 4.267 ± 2.5291 | 4.198 ± 1.9390 | 4.009 ± 0.9526 | 4.031 ± 1.6109 |
Change in Weight-SDS (Standard Deviation Score)
| Standard Deviation Score | LUM-201 (0.8 mg/kg/Day) | LUM-201 (1.6 mg/kg/Day) | LUM-201 (3.2 mg/kg/Day) | rhGH (34 µg/kg/Day) |
|---|---|---|---|---|
| Change in Weight SDS | 0.322 ± 0.3149 | 0.370 ± 0.2817 | 0.558 ± 0.2139 | 0.171 ± 0.1414 |
Change in Weight-SDS (Standard Deviation Score)
| Standard Deviation Score | LUM-201 (0.8 mg/kg/Day) | LUM-201 (1.6 mg/kg/Day) | LUM-201 (3.2 mg/kg/Day) | rhGH (34 µg/kg/Day) |
|---|---|---|---|---|
| Change in Weight SDS | 0.537 ± 0.5800 | 0.446 ± 0.2912 | 0.611 ± 0.2695 | 0.392 ± 0.3261 |
Change in BMI from baseline
| kg/m2 | LUM-201 (0.8 mg/kg/Day) | LUM-201 (1.6 mg/kg/Day) | LUM-201 (3.2 mg/kg/Day) | rhGH (34 µg/kg/Day) |
|---|---|---|---|---|
| Change in Body Mass Index (BMI) | 0.74 ± 0.741 | 0.80 ± 0.643 | 0.87 ± 0.483 | -0.19 ± 0.623 |
Change in BMI (Body Mass Index) from baseline
| kg/m2 | LUM-201 (0.8 mg/kg/Day) | LUM-201 (1.6 mg/kg/Day) | LUM-201 (3.2 mg/kg/Day) | rhGH (34 µg/kg/Day) |
|---|---|---|---|---|
| Change in BMI | 1.12 ± 1.305 | 0.84 ± 0.910 | 0.95 ± 0.480 | 0.26 ± 1.018 |
Change in BMI SDS
| Standard Deviation Score | LUM-201 (0.8 mg/kg/Day) | LUM-201 (1.6 mg/kg/Day) | LUM-201 (3.2 mg/kg/Day) | rhGH (34 µg/kg/Day) |
|---|---|---|---|---|
| Change in BMI SDS | 0.286 ± 0.3311 | 0.318 ± 0.2852 | 0.460 ± 0.3091 | -0.205 ± 0.3064 |
Change in BMI SDS This is not a Z-Score analysis. Standard deviation score of 0 is the population mean for the age/sex. Normal range is typically -2 to +2 SDS. A positive score is an improvement and a negative score a decrease.
| Standard Deviation Score | LUM-201 (0.8 mg/kg/Day) | LUM-201 (1.6 mg/kg/Day) | LUM-201 (3.2 mg/kg/Day) | rhGH (34 µg/kg/Day) |
|---|---|---|---|---|
| Change in BMI SDS | 0.317 ± 0.5017 | 0.169 ± 0.4053 | 0.411 ± 0.3097 | -0.075 ± 0.4969 |
Change in bone age, measured by X-ray of left hand and wrist using Greulich \& Pyle atlas
| Years | LUM-201 (0.8 mg/kg/Day) | LUM-201 (1.6 mg/kg/Day) | LUM-201 (3.2 mg/kg/Day) | rhGH (34 µg/kg): |
|---|---|---|---|---|
| Bone Age | 0.455 ± 0.2002 | 0.485 ± 0.3708 | 0.439 ± 0.2149 | 0.539 ± 0.2735 |
Change in bone age, measured by X-ray of left hand and wrist using Greulich \& Pyle atlas
| Years | LUM-201 (0.8 mg/kg/Day) | LUM-201 (1.6 mg/kg/Day) | LUM-201 (3.2 mg/kg/Day) |
|---|---|---|---|
| Bone Age | 1.1515 ± 0.5647 | 1.862 ± 0.4799 | 1.585 ± 0.4960 |
Serum concentrations at 30 minutes (Cmax/Steady State)
| Concentration (ng/mL) | LUM-201 (0.8 mg/kg/Day) | LUM-201 (1.6 mg/kg/Day) | LUM-201 (3.2 mg/kg/Day) |
|---|---|---|---|
| Day 1 | 55.2 ± 20.5 | 154 ± 37.2 | 186 ± 163 |
| Month 1 | 14.2 ± 46.6 | 66.2 ± 46.3 | 165 ± 283 |
| Month 6 | 42.2 ± 32.4 | 71.6 ± 58.6 | 152 ± 205 |
Serum GH concentration
| ng/ml | LUM-201 (0.8 mg/kg/Day) | LUM-201 (1.6 mg/kg/Day) | LUM-201 (3.2 mg/kg/Day) | rhGH (34 µg/kg/Day) |
|---|---|---|---|---|
| Growth Hormone (GH) Concentration on Maintenance Treatment | 9.16 ± 6.501 | 7.36 ± 4.384 | 7.51 ± 3.815 | — |
Serum GH concentration
| ng/ml | LUM-201 (0.8 mg/kg/Day) | LUM-201 (1.6 mg/kg/Day) | LUM-201 (3.2 mg/kg/Day) | rhGH (34 µg/kg/Day) |
|---|---|---|---|---|
| Growth Hormone (GH) Concentration on Maintenance Treatment | 10.84 ± 10.831 | 6.45 ± 5.720 | 8.53 ± 6.339 | — |
Serum concentrations of insulin-like growth factor 1 This is not a Z-Score analysis. Standard deviation score of 0 is the population mean for the age/sex. Normal range is typically -2 to +2 SDS. A positive score is an improvement and a negative score a decrease.
| Standard Deviation Score | LUM-201 (0.8 mg/kg/Day) | LUM-201 (1.6 mg/kg/Day) | LUM-201 (3.2 mg/kg/Day) | rhGH (34 µg/kg/Day) |
|---|---|---|---|---|
| Insulin-like Growth Factor 1 SDS | -0.296 ± 1.0677 | 0.078 ± 0.6447 | 0.116 ± 0.9318 | 0.524 ± 0.8233 |
Serum concentrations of insulin-like growth factor 1 This is not a Z-Score analysis. Standard deviation score of 0 is the population mean for the age/sex. Normal range is typically -2 to +2 SDS. A positive score is an improvement and a negative score a decrease.
| Standard Deviation Score | LUM-201 (0.8 mg/kg/Day) | LUM-201 (1.6 mg/kg/Day) | LUM-201 (3.2 mg/kg/Day) | rhGH (34 µg/kg/Day) |
|---|---|---|---|---|
| Insulin-like Growth Factor 1 SDS | -0.231 ± 1.1169 | -0.212 ± 0.7052 | 0.165 ± 1.1261 | 1.111 ± 1.1737 |
Collected over 2 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PEM Dose LUM-201 (0.8 mg/kg/Day) | 0/104 (0%) | 1/104 (1%) | 22/104 (21.2%) |
| LUM-201 (0.8 mg/kg/Day) | 0/18 (0%) | 1/18 (5.6%) | 14/18 (77.8%) |
| LUM-201 (1.6 mg/kg/Day) | 0/22 (0%) | 1/22 (4.5%) | 21/22 (95.5%) |
| LUM-201 (3.2 mg/kg/Day) | 0/22 (0%) | 0/22 (0%) | 20/22 (90.9%) |
| rhGH (34 µg/kg/Day) | 0/20 (0%) | 1/20 (5%) | 17/20 (85%) |
| Event | PEM Dose LUM-201 (0.8 mg/kg/Day) | LUM-201 (0.8 mg/kg/Day) | LUM-201 (1.6 mg/kg/Day) | LUM-201 (3.2 mg/kg/Day) | rhGH (34 µg/kg/Day) |
|---|---|---|---|---|---|
| Cartilage development disorderMusculoskeletal and connective tissue disorders | 0/104 | 1/18 | 0/22 | 0/22 | 0/20 |
| GlycosuriaRenal and urinary disorders | 0/104 | 0/18 | 0/22 | 0/22 | 1/20 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/104 | 0/18 | 1/22 | 0/22 | 0/20 |
| DeyhdrationMetabolism and nutrition disorders | 1/104 | 0/18 | 0/22 | 0/22 | 0/20 |
| Event | PEM Dose LUM-201 (0.8 mg/kg/Day) | LUM-201 (0.8 mg/kg/Day) | LUM-201 (1.6 mg/kg/Day) | LUM-201 (3.2 mg/kg/Day) | rhGH (34 µg/kg/Day) |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 4/104 | 5/18 | 8/22 | 6/22 | 5/20 |
| Upper respiratory tract infectionInfections and infestations | 0/104 | 1/18 | 4/22 | 7/22 | 5/20 |
| COVID-19Infections and infestations | 1/104 | 1/18 | 6/22 | 4/22 | 3/20 |
| Viral infectionInfections and infestations | 0/104 | 1/18 | 5/22 | 0/22 | 1/20 |
| PyrexiaGastrointestinal disorders | 0/104 | 3/18 | 2/22 | 5/22 | 0/20 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/104 | 4/18 | 3/22 | 3/22 | 1/20 |
| VomitingGastrointestinal disorders | 3/104 | 0/18 | 2/22 | 4/22 | 4/20 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/104 | 3/18 | 3/22 | 2/22 | 3/20 |
| NasopharyngitisInfections and infestations | 0/104 | 1/18 | 1/22 | 2/22 | 3/20 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/104 | 0/18 | 0/22 | 0/22 | 3/20 |
PEM Dose LUM-201 (0.8 mg/kg/day) was not considered a dose arm as it was a qualification that needed to be met in order for subjects to enter the study.
| Age, Categorical(Participants) | LUM-201 (0.8 mg/kg/Day) | LUM-201 (1.6 mg/kg/Day) | LUM-201 (3.2 mg/kg/Day) | rhGH (34 µg/kg/Day) | Total |
|---|---|---|---|---|---|
| <=18 years | 18 | 22 | 22 | 20 | 82 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(months) | LUM-201 (0.8 mg/kg/Day) | LUM-201 (1.6 mg/kg/Day) | LUM-201 (3.2 mg/kg/Day) | rhGH (34 µg/kg/Day) | Total |
|---|---|---|---|---|---|
| Mean | 101.3 ± 29.18 | 95.2 ± 27.26 | 94.5 ± 21.07 | 91.4 ± 23.26 | 95.5 ± 25.01 |
| Sex: Female, Male(Participants) | LUM-201 (0.8 mg/kg/Day) | LUM-201 (1.6 mg/kg/Day) | LUM-201 (3.2 mg/kg/Day) | rhGH (34 µg/kg/Day) | Total |
|---|---|---|---|---|---|
| Female | 7 | 11 | 10 | 8 | 36 |
| Male | 11 | 11 | 12 | 12 | 46 |
| Race (NIH/OMB)(Participants) | LUM-201 (0.8 mg/kg/Day) | LUM-201 (1.6 mg/kg/Day) | LUM-201 (3.2 mg/kg/Day) | rhGH (34 µg/kg/Day) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 1 | 1 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 16 | 20 | 20 | 18 | 74 |
| More than one race | 1 | 1 | 1 | 1 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Bone Age (BA)(years) | LUM-201 (0.8 mg/kg/Day) | LUM-201 (1.6 mg/kg/Day) | LUM-201 (3.2 mg/kg/Day) | rhGH (34 µg/kg/Day) | Total |
|---|---|---|---|---|---|
| Mean | 6.542 ± 2.4882 | 5.905 ± 2.3835 | 5.715 ± 1.9553 | 5.570 ± 1.9709 | 5.912 ± 2.1914 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Dec 2020 to primary completion in Sep 2024, 44 months.
Results were first posted in Jun 2026, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibutamoren